Tirzepatide
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
Eli Lilly · Phase 2 · Recruiting · Enrollment 372
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| HDM1005 injection dose group 1 | Obesity or overweight | n/r | 52 | n/r | n/r |
| HDM1005 injection dose group 2 | Obesity or overweight | n/r | 52 | n/r | n/r |
| HDM1005 injection dose group 3 | Obesity or overweight | n/r | 52 | n/r | n/r |
| tirzepatide injection | Obesity or overweight | n/r | 52 | n/r | n/r |